Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03826602 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03826602 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 18 participants.
The verdict
NCT03826602, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is being done to look at how tucatinib might affect the way another drug (metformin) works. It will look at healthy volunteers and how tucatinib affects how the body absorbs metformin. This will help us find out whether tucatinib is safe to give together with metformin. The study will also look at how tucatinib affects how the kidneys work.
Interventions
- DRUG Metformin
- DRUG Tucatinib
- DRUG Iohexol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03826602
The ClinicalTrials.gov registry entry for NCT03826602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT03826602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03826602 about?
NCT03826602 is a clinical study titled "A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin". This study is being done to look at how tucatinib might affect the way another drug (metformin) works. It will look at healthy volunteers and how tucatinib affects how the body absorbs metformin. This will help us find out whether tucatinib is safe to give together with metformin. The study will als...
What is the current status of trial NCT03826602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-02-12. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03826602?
The interventions under investigation include: Metformin (DRUG), Tucatinib (DRUG), Iohexol (DRUG).
Who is sponsoring clinical trial NCT03826602?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.